All In Biotech

Drug Trial Radar · NCT07903415

A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08098488 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS.

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Nov 5, 2026

Primary completion

Jan 26, 2031

Study completion Jan 26, 2032

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08098488) in people with advanced solid tumors (cancer that cannot be removed with surgery or has spread to other parts of the body). PF-08098488 is being studied as a possible treatment for certain types of cancer. These include non-small cell lung cancer, pancreatic cancer, stomach or gastroesophageal junction cancer, and esophageal cancer. This study will also help researchers learn how the study medicine moves through and affects the body. This study is seeking adults who: * Have advanced non-small cell lung cancer, pancreatic cancer, stomach or gastroesophageal junction cancer, or esophageal cancer. * Have received at least 1 previous treatment for their cancer. * Have cancer that has grown, returned, or is no longer responding to available treatments. All participants in this study will receive PF-08098488 as an IV infusion (given directly into a vein) at the study clinic. Researchers will study different dose levels and dosing schedules to find the dose that is safe and may work best. Participants will be monitored closely during treatment, especially after their first infusion. They may continue receiving the study medicine as long as their cancer is not getting worse and they are tolerating treatment. The study includes a screening period of up to 28 days. Participants will have regular visits to the study clinic for treatment and health assessments. These assessments include scans to monitor the cancer and blood sample collection. Tumor tissue samples will also be collected when available or medically feasible. After treatment ends, participants will have a follow-up visit about 1 month later. They will then be contacted about every 12 weeks to check on their health.

Conditions

  • Pancreatic Ductal Adenocarcinoma
  • Esophageal Cancer
  • Carcinoma, Non-Small-Cell Lung (NSCLC)
  • Gastric Carcinoma
  • Gastroesophageal Junction Adenocarcinoma

Interventions

  • PF-08098488Drug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: Start of study treatment to 30 days after the last dose of study drug administration or start of new anticancer therapy (whichever occurs first)
  2. Part 1: Recommended Monotherapy Dose(s) for Expansion (RDEM)Time frame: From first dose through completion of Part 1, an average of 1 year
  3. Part 2: Recommended Monotherapy Dose for Further DevelopmentTime frame: From first dose through completion of Part 2, an average of 2 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • START Midwest, LLC

    Grand Rapids, Michigan · Recruiting

  • Sarah Cannon Research Institute - Pharmacy

    Nashville, Tennessee · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • START San Antonio, LLC

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.